This research provides foundational evidence that targeting the glucose/NSUN2/TREX2 axis is a promising strategy for overcoming resistance to PD-1/PD-L1 immune therapies in cold tumors, offering a basis for converting prostate cancer and other cold tumors into hot tumors that respond to PD-1/PD-L1 immune therapy (16). The gene discussed is CD274; the disease is prostate cancer.